MedTrace Logo

Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival

NCT03417050 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2636

Last updated 2020-01-29

No results posted yet for this study

Summary

An investigator-driven, retrospective study to compare long-term survival-data (10-year follow-up) of patients with coronary artery disease (CAD), previously enrolled in the SYNTAX trial, who were randomized to percutaneous coronary intervention (PCI) using a paclitaxel (TAXUS) drug-eluting-stent (DES) or coronary artery bypass grafting (CABG).

Conditions

Interventions

OTHER

No intervention will take place for this retrospective and observational study.

No intervention will take place for this retrospective and observational study.

Sponsors & Collaborators

Principal Investigators

  • A. Pieter Kappetein, MD, PhD · Erasmus Medical Center

  • Friedrick W. Mohr, MD, PhD · German Heart Center, Leipzig, Germany

  • Patrick W.J.C. Serruys, MD, PhD · Imperial College London

  • Michael J. Mack, MD, PhD · Baylor Scott & White Health, Plano, TX, United States

  • David R. Holmes, MD · Mayo Clinic, Rochester, MN, United States

  • Marie-Claude Morice, MD · ICPS Ramsay-Generale de Sante, Massy, France

  • Piroze M. Davierwala, MD · German Heart Center, Leipzig, Germany

  • Stuart J. Head, MD, PhD · Erasmus Medical Center

  • Daniel J.F.M. Thuijs, MD · Erasmus Medical Center

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-08-08
Completion
2019-08-08

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03417050 on ClinicalTrials.gov